Molecular Therapy: Oncology
Издатель: Elsevier · ISSN 2950-3299 · 73 статей
- Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies
- Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes
- A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia
- Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses
- Reversible control of CAR T cells through PROTAC compound targeting bromodomain mutant
- Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma
- Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids
- Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy
- Oncolytic virus-mediated remodeling of tumor microenvironment enhances efficacy of an HPV16 E6/E7 mRNA vaccine in an HPV-positive tumor
- Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner
- Lnk Governs chemokine-directed trafficking of CD8+ T cells in melanoma
- Angiopoietin-like protein 4 deficiency promotes tumor immune infiltration and CD8+ T cell cytotoxic activity to inhibit tumor progression
- Oncolytic adenovirus incorporating TetO sites in the E1A promoter for controlled replication in TetR-expressing mesenchymal stem cells
- Arming oncolytic Coxsackievirus B3 with Neoleukin-2/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation
- TAP1 deficiency reshapes tumor antigenicity and enables CD8 T cell targeting in colorectal cancer
- Neuroepithelial reprogramming and ERBB vulnerability in canine acanthomatous ameloblastoma
- Balancing corticosteroids and viral therapies in glioblastoma
- Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors
- KIR3DL3 Silencing Relieves B7H7-Mediated Suppression and Enhances CAR-T Cell Therapy in Pancreatic Cancer
- An efficient Degron/CRISPR combination system for rapid generation of MVA vaccine vectors
- Eradication of pre-clinical prostate tumors by a lentiviral vector-based immunotherapy
- ICAM1-targeted costimulation extends HER2 CAR T cytotoxicity to HER2-low and HER2-negative tumors through synergy with TCR signaling
- Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma
- Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses
- Selective Inhibition of EGFR-mutant Lung Cancer Cell Proliferation by CRISPR/Cas9 Targeting
- Engineered indoleamine 2,3-dioxygenase variant: Oxidative activation of prodrug indole-3-acetic acid against cancer cells for targeted therapy
- CAR design equips diverse immune cells with unique antigen-specific activation identities
- Prevention of HNSCC by chewing gum delivery of enzymes/antimicrobials to reduce carcinogenic acetaldehyde produced by pathogenic microbes
- An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy
- IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting